U.S. FDA says Epix’s Vasovist cleared for sale

WASHINGTON (Reuters) - U.S. regulators have approved Epix Pharmaceuticals Inc’s Vasovist imaging agent to help detect blood vessel problems, the U.S. Food and Drug Administration said on Wednesday.

Epix, which announced the approval on Monday, has said the injectable product can help doctors better track the flow of blood seen in scans and find blockages or other vessel complications.

The FDA released its decision on its website here

(Editing by Maureen Bavdek)


Related Posts:

WASHINGTON (Reuters) - A review of clinical trial data from four drugmakers shows no overall risk of heart problems in patients taking drugs to treat osteoporosis, the U.S. Food and Drug Administration said on Wednesday. The agency reviewed studies on Merck & Co’s Fosamax, Roche’s Boniva, Novartis AG’s Reclast and Procter and Gamble Co’s Actonel and

Full Post: Studies do not link heart risk to bone drugs: FDA

By Gene Emery BOSTON (Reuters) - The U.S. health insurance program for the elderly, Medicare, is spending money on state-of-the-art CT scanners without clear evidence showing their usefulness in combating heart problems, commentators in the New England Journal of Medicine said on Wednesday. CT scanning, used to diagnose coronary artery blockages, is one case where the U.S.

Full Post: Scientists doubt utility of CT scan as heart test

WASHINGTON (Reuters) - Data on Pfizer Inc’s smoking cessation drug Chantix continue to back the product’s safety, the company said on Wednesday after a watchdog group called for stronger warnings about risks. Based on all data including clinical trials, “we stand by the efficacy and safety profile of Chantix when used as directed, an important treatment

Full Post: Pfizer says data support quit-smoking drug’s safety

WASHINGTON (Reuters) - Makers of epilepsy drugs must add a warning that the medicines carry a risk of suicidal thoughts or actions, U.S. health officials said on Tuesday. “The risk of suicidal thoughts or behavior was generally consistent among the eleven drugs analyzed and was observed in patients who were treated for epilepsy, psychiatric disorders, and

Full Post: FDA orders suicidal action warning on epilepsy drugs

WASHINGTON (Reuters) - U.S. health officials proposed paying for wider use of PET scans to help doctors decide the initial course of treatment in some cancer patients, the Centers for Medicare & Medicaid Services said on Tuesday. CMS said in a draft proposal that it would allow most Medicare patients to undergo one positron emission tomography

Full Post: Medicare proposes wider cancer scan coverage

Site Navigation

Most Read



  • kinwrite.com@gmail.com